The estimated Net Worth of Thomas Charles Reilly is at least 252 千$ dollars as of 1 July 2024. Mr Reilly owns over 16,667 units of Cara Therapeutics Inc stock worth over 29,729$ and over the last 4 years he sold CARA stock worth over 51,405$. In addition, he makes 170,590$ as Chief Financial Officer at Cara Therapeutics Inc.
Mr has made over 8 trades of the Cara Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 16,667 units of CARA stock worth 4,833$ on 1 July 2024.
The largest trade he's ever made was exercising 51,500 units of Cara Therapeutics Inc stock on 10 January 2024 worth over 14,935$. On average, Mr trades about 12,529 units every 65 days since 2020. As of 1 July 2024 he still owns at least 102,514 units of Cara Therapeutics Inc stock.
You can see the complete history of Mr Reilly stock trades at the bottom of the page.
Thomas Charles Reilly is the Chief Financial Officer at Cara Therapeutics Inc.
As the Chief Financial Officer of Cara Therapeutics Inc, the total compensation of Mr Reilly at Cara Therapeutics Inc is 170,590$. There are 13 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of 3,736,190$.
Mr Reilly is 49, he's been the Chief Financial Officer of Cara Therapeutics Inc since . There are 14 older and 3 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over 25,200,591$ worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth 19,406,983$ . The most active insiders traders include Edward Hurwitz、Martin Vogelbaum、Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of 5,343$. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth 1,452$.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: